| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 31.27% | 32.63% | 27.10% | 27.11% | 14.97% | 12.70% | 14.53% | 14.94% | 17.71% | 14.88% | 12.13% | 13.12% |
| Operating Margin | -13.38% | -6.90% | -21.11% | -22.23% | -2.48% | -6.53% | 0.98% | 2.59% | 3.30% | -4.15% | 3.42% | 4.23% |
| EBITDA Margin | -7.15% | 0.01% | -8.24% | -12.60% | 1.17% | -3.34% | 3.71% | 4.96% | 5.57% | -2.18% | 4.74% | 5.73% |
| Net Margin | -30.04% | 9.37% | -96.41% | -52.44% | -6.00% | -6.47% | 0.07% | 4.74% | 2.25% | -2.44% | 2.51% | 4.02% |
| Current Ratio | 2.84 | 2.08 | 2.39 | 0.61 | 1.23 | 0.87 | 0.97 | 1.10 | 1.58 | 1.53 | 1.66 | 1.88 |
| Quick Ratio | 1.77 | 1.06 | 1.35 | 0.41 | 0.91 | 0.69 | 0.58 | 0.74 | 1.09 | 1.08 | 1.21 | 1.37 |
| Debt / Equity | 100.20 | 8.98 | -20.06 | 2.76 | 0.80 | 0.45 | 0.36 | 0.17 | 0.21 | 0.26 | 0.19 | 0.17 |
| ROE | -2897.98% | 106.17% | 2353.74% | -136.95% | -20.93% | -18.36% | 0.15% | 9.83% | 4.64% | -5.48% | 6.15% | 9.35% |
| ROA | -16.18% | 4.73% | -39.27% | -35.30% | -7.75% | -7.67% | 0.08% | 6.14% | 2.95% | -3.39% | 3.91% | 6.10% |
| Asset Turnover | 0.54 | 0.51 | 0.41 | 0.67 | 1.29 | 1.19 | 1.07 | 1.30 | 1.31 | 1.39 | 1.56 | 1.52 |
| Book Value / Share | 0.04 | 0.31 | -0.14 | 2.41 | 5.33 | 7.13 | 9.44 | 9.05 | 8.25 | 7.85 | 8051.98 | 7.55 |
Lifecore Biomedical Inc. is a prominent entity in the biotechnology sector, primarily engaged in the manufacture and development of high-quality biomedical products. The company specializes in the production of hyaluronan and other polysaccharide-based products for medical applications. These biomaterials are crucial in various medical fields, including ophthalmology, orthopedics, and general surgery, thanks to their biocompatibility and multifunctional characteristics. Lifecore Biomedical Inc.'s expertise in manufacturing and formulation is underscored by its integration with the pharmaceutical and health industries, where its products are utilized in drug delivery systems and surgical applications. Established with a commitment to quality and innovation, the company plays a significant role in advancing medical technology and improving patient outcomes globally. Its presence in the market underscores the critical interface between leading-edge biotechnology and practical health applications, making it a key player in the advancement of medical treatments and technologies.